Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis - Contacts and Locations

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

This study is ongoing, but not recruiting participants.

Study NCT00012467. Last updated on June 23, 2005. Information provided by NIH AIDS Clinical Trials Information Service

Please refer to this study by its ClinicalTrials.gov identifier: NCT00012467

Locations


United States, Alabama
	Univ of Alabama at Birmingham
	Birmingham, Alabama, United States, 35294

United States, Missouri
	Washington Univ
	St. Louis, Missouri, United States, 63108

United States, New Jersey
	UMDNJ - New Jersey Med School / Cooper Hosp
	Camden, New Jersey, United States, 08103
	Univ of Med & Dentistry of New Jersey
	Newark, New Jersey, United States, 07103

United States, Texas
	Houston Veterans Administration Med Ctr
	Houston, Texas, United States, 77030
	Audie L Murphy Veterans Administration Hosp
	San Antonio, Texas, United States, 78284
	Univ of Texas / Med School at Houston
	Houston, Texas, United States, 77030

Peru
	Instituto de Medicina Tropical
	Lima, Peru
	Hosp Nacional dos de Mayo
	Lima, Peru

Sponsors and Collaborators

InterMune